ASCO 24: Data shows survival benefit with J&J’s subcutaneous Rybrevant

At the ongoing American Society of Clinical Oncology (ASCO) Annual Meeting, being held 31 May—4 June, primary results were presented for the PALOMA-3 study investigating a subcutaneous formulation (SC) for Johnson and Johnson Innovative Medicine’s (J&J) bispecific antibody Rybrevant (amivantamab).